Physician
Visconti, Ann Marie
Visconti, Ann Marie was paid $94K by Medicaid between May 2018 and Jul 2023, across 4 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 72% of everything it billed.
33Billing provider infoVISCONTI, ANN MARIE
PITTSFIELD, MA 01201
PITTSFIELD, MA 01201
33aNPI1841363215assigned 11/15/2006
33bProvider typeOtolaryngology Physician
28Total paid$94K
24GClaims1,320
24DCodes billed4
24AFirst – last monthMay 2018 – Jul 2023
Compared with peers
Next to other Otolaryngology Physician providers in Massachusetts
Rank by total paid#17 of 90
Median peer was paid$14K
This provider vs. median6.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 127 | $8K | |
| 2019 | 261 | $14K | |
| 2020 | 178 | $11K | |
| 2021 | 56 | $3K | |
| 2022 | 156 | $12K | |
| 2023 | 542 | $45K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 72% | 756 | 607 | $67K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 24% | 494 | 370 | $23K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.3% | 57 | 54 | $3K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | <1% | 13 | 13 | $856.05 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.